NewEdge Wealth LLC increased its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 36.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 107,756 shares of the biopharmaceutical company’s stock after acquiring an additional 28,693 shares during the quarter. NewEdge Wealth LLC’s holdings in Pfizer were worth $2,683,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Horizon Financial Services LLC increased its stake in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the period. YANKCOM Partnership purchased a new position in Pfizer in the 4th quarter worth about $28,000. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer in the 3rd quarter worth about $29,000. Darwin Wealth Management LLC purchased a new position in Pfizer in the 2nd quarter worth about $32,000. Finally, Torren Management LLC purchased a new position in Pfizer during the 4th quarter valued at about $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the stock. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research report on Monday, March 2nd. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research report on Thursday, February 12th. CICC Research assumed coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price on the stock. Finally, Royal Bank Of Canada reissued an “underperform” rating and set a $25.00 target price on shares of Pfizer in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $28.74.
Pfizer Stock Up 0.3%
NYSE:PFE opened at $25.88 on Wednesday. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75. The stock has a market capitalization of $147.51 billion, a P/E ratio of 19.76 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company’s 50-day simple moving average is $27.05 and its 200-day simple moving average is $26.18.
Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period last year, the business earned $0.92 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.
Pfizer News Roundup
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Several articles argued that Pfizer looks “dirt cheap” and could be a long-term buy, reinforcing the view that the stock may have room to recover as investors focus on valuation and future growth potential. Article Title
- Positive Sentiment: Pfizer and partner Arvinas reached a licensing transaction with Rigel Pharmaceuticals for the breast cancer drug VEPPANU (vepdegestrant), bringing in $85 million upfront and up to $320 million more in milestones plus royalties, which supports future cash flow and validates the asset. Article Title
- Positive Sentiment: Additional coverage highlighted Pfizer’s earnings as stronger than the market expected, suggesting the company’s recent quarter may have been better than the stock’s muted reaction implied. Article Title
- Neutral Sentiment: Commentary on Pfizer’s dividend raised questions about sustainability, but the discussion also noted the yield remains unusually high and could appeal to income-focused investors. Article Title
- Neutral Sentiment: Analysts and market commentators continued to debate Pfizer’s long-term outlook, including whether oncology and next-generation therapies can offset the post-COVID revenue decline. Article Title
- Negative Sentiment: Coverage also noted pressure on vaccine makers from softer U.S. demand and tougher policy conditions, a reminder that Pfizer’s vaccine-related businesses may face ongoing headwinds. Article Title
Pfizer Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Articles
- Five stocks we like better than Pfizer
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
